Central-type primitive neuroectodermal tumor of the uterus: Case report of remission of stage IV disease using adjuvant cisplatin/etoposide/bevacizumab chemotherapy and review of the literature  by Novo, Jorge et al.
Gynecologic Oncology Reports 14 (2015) 26–30
Contents lists available at ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /goreCase reportCentral-type primitive neuroectodermal tumor of the uterus: Case report
of remission of stage IV disease using adjuvant cisplatin/etoposide/
bevacizumab chemotherapy and review of the literatureJorge Novo a,⁎, Pincas Bitterman a, Alfred Guirguis b
a Rush University Medical Center, Department of Pathology, 1653 West Congress Parkway, 570 Jelke, Chicago, IL 60612, United States
b Gynecologic Cancer Institute of Chicago, 5716 W 95th Street, Oak Lawn, IL 60453, United States⁎ Corresponding author.
E-mail address: Jorge_E_Novo@rush.edu (J. Novo).
http://dx.doi.org/10.1016/j.gore.2015.09.002
2352-5789/© 2015 The Authors. Published by Elsevier Inca r t i c l e i n f o their presentation, management, and outcomes (Table 1). We reportArticle history:
Received 19 June 2015
Received in revised form 30 August 2015
Accepted 13 September 2015
Available online 16 September 2015
Keywords:
Primitive neuroectodermal tumor
Uterine neoplasm
Uterine PNET
Central-type PNET
cPNET
Bevacizumab
an additional case of cPNETs of the uterine corpus, with this being the
ﬁrst case treated with surgical debulking and adjuvant cisplatin,
etoposide and bevacizumab, with no evidence of disease recurrence
forty-eight months following intervention.
2. Case report
A 26 year-old nulligravid, Hispanic female presented to an outside
institution with dysfunctional uterine bleeding for four months. She
was treated with oral contraceptives without resolution of her symp-
toms. A transvaginal ultrasound was performed, which showed an en-
larged uterus with a 5.7 × 7 × 7 cm homogenous mass located within1. Introduction
Primitive neuroectodermal tumors (PNETs) are rare neoplasms that
can occur in the female genital tract, among other visceral sites. The
most common location within the female genital tract is the ovary,
followed by the uterine corpus (Euscher et al., 2008), vagina, and cervix
(Snijders-Keilhotlz et al., 2005).
PNETs can present in pure form or admixed with other components,
including endometrioid adenocarcinoma, adenosarcoma, carcinosarco-
ma (metaplastic carcinoma), and heterologous sarcomas (Nogales,
2003; Bartosch et al., 2011). When considering PNET as a diagnosis,
the differential should include poorly-differentiated endometrioid car-
cinoma, non-keratinized squamous cell carcinoma, endometrial stromal
sarcoma, lymphoma, small cell neuroendocrine carcinoma, and
metastasis.
To date, over 58 cases of uterine PNETs have been published in the
literature, the largest being a seventeen-patient case series by Euscher
et al. (2008). While these cases share the same diagnosis, they vary in. This is an open access article underthe lower uterine segment, as well as an enlarged right ovary. An endo-
metrial biopsy showed endometrial tissue with possible small cell
neuroectodermal tumor. The patient was then referred to our institu-
tion where a repeat endometrial biopsy showed high-grade malignant
tumor inﬁltrating cervical tissue, favoring PNETs. A computed tomogra-
phy (CT) study demonstrated a large uterus measuring up to 8.2 cm in
widthwith a 5.8 × 4.2 cmmass within themyometrium, a 4.1 cm cystic
lesion in the right adnexa, ascites, a left-sided pleural effusion, andmild-
ly enlarged para-aortic lymph nodes. Dilatation and curettagewere per-
formed, and pathologic examination revealed a high grade malignant
tumor, favoring PNETs. The patient then underwent an exploratory lap-
arotomy with radical tumor debulking, total abdominal hysterectomy
with pelvic lymphadenectomy, bilateral salpingo-oophorectomy,
omentectomy, and removal of tumor from the posterior cul-de-sac.
Intra-operative ﬁndings were consistent with stage IV uterine cancer.
Although the patient was optimally surgically debulked, there was still
residual tumor measuring less than 1 cm at the conclusion of the
procedure.2.1. Pathology
On gross examination, the uterus contained an exophytic
7.1 × 6.0 × 2.6 cm white-tan marbled mass with areas of hemorrhage
and necrosis, occupying the entirety of the endometrial cavity, and inﬁl-
trating the full thickness of the myometrium (2.6 cm). In addition, the
mass involved both right (7.1 × 5.5 × 2.5 cm) and left ovaries
(4.8 × 2.6 × 2.4 cm), with extension from the fallopian tubes.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics, surgical management, adjuvant chemotherapy, and follow-up of reported cases of uterine PNET.
Author Age Initial sign/symptom FIGO
stage
Surgery Chemotherapy Follow-up
Bartosch et al.
(2011)
58 Vaginal bleeding, abdominal
pain, weight loss
IV TAH, BSO, segmental enterectomy,
total colectomy, right PLND
Carboplatin
Paclitaxel
Died, 11 months with sepsis
from pyelonephritis
Celik et al. 32 Abdominal pain, pelvic mass IIIA TAH, BSO, PLND, PALND,
omentectomy, appendectomy
Cisplatin
Ifosfamide
Adriamycin
Vincristine
(PIAV)
NED, 38 months
Bhardwaj et al. 50 Vaginal bleeding, pelvic mass IIIC TAH, BSO, omentectomy, PLND Unknown chemotherapy
regimen
NED, 6 months
Odunsi et al. (2004) 66 Vaginal bleeding I TAH, BSO, omentectomy, PLND, PALND Not done NED, 2 years
Odunsi et al. (2004) 65 Vaginal bleeding IIIC TAH, BSO, omentectomy, PLND,
PALND, upper vaginectomy
Cisplatin
Doxorubicin
Etoposide
Paclitaxel
Lung metastasis, 3 months
AWD, 12 months
Karseladze et al. 16 Vaginal bleeding I TAH, BSO, omentectomy Vincristine
Cyclophosphamide
Doxorubicin
NED, 4 years
Hendrickson and
Scheithauer
12 Vaginal bleeding, pelvic mass IVB TAH, LSO Cyclophosphamide
Doxorubicin
Vincristine
Pelvic recurrence, 12 months
DOD, 2 years
Hendrickson and
Scheithauer
57 Vaginal bleeding, uterine
mass
IIB TAH, BSO, PALND Cisplatin
Vinblastine
Bleomycin
Lung metastasis, 5 months
DOD, 2 years
Rose et al.
Ward et al.
17 Vaginal bleeding, pelvic mass IIIC RH, PLND, bilateral ovarian wedge
biopsy
Vincristine
Cisplatin
Doxorubicin
Dactinomycin
Cyclophosphamide
Etoposide
NED, N10 years
Daya et al. 67 Vaginal bleeding, enlarged
uterus
IIIC SCH, BSO Cisplatin
Doxorubicin
Carboplatin
5-FU
Persistent
DOD, 6 months
Daya et al. 68 Vaginal bleeding, enlarged
uterus
IVB TAH, BSO, PLND Cisplatin Persistent
DOD, 12 months
Daya et al. 69 Vaginal bleeding I TAH, BSO, PLND Not done NED, 6 years
Daya et al. 68 Vaginal bleeding I TAH, BSO Not done NED, 5 years
Molyneux et al. 72 Vaginal bleeding I TAH, BSO Not done DOD, 8 months
Fragetta et al. 78 Vaginal bleeding IB TAH, BSO, PLND Not done NED, 9 months
Sorenson et al. 62 Vaginal bleeding I TAH, BSO Vincristine
Cyclophosphamide
Cisplatin
DOD, 18 months
Taieb et al. 36 Uterine enlargement I RH, BSO, PLND Not done NR
Ng et al. 48 Vaginal bleeding IIIC TAH, BSO Not done
Blattner et al. (2007) 26 Pelvic mass noted at cesarean
section
III RH, PLND, bilateral ovarian
transposition
Vincristine
Doxorubicin
Cyclophosphamide
Etoposide
NED, 16 months
Mittal et al. (2007) 24 Fever, abdominal pain, pelvic
mass
II TAH, BSO, omentectomy Vincristine
Doxorubicin
Cyclophosphamide
Ifosfamide
Etoposide
Recurrence, 1 months
Akbayir et al. 22 Vaginal bleeding, adnexal
mass
I TAH, BSO, PLND, PALND,
omentectomy
Cisplatin
Doxorubicin
NED, 10 months
Peres et al. 15 Abdominal pain, fever, pelvic
mass
I TAH, PLND Carboplatin
Etoposide
NED, 12 months
Varghese et al.
(2006)
43 Vaginal bleeding, uterine
enlargement
IIIC TAH, BSO, PLND Cytoxan
Adriamycin
Vincristine
Etoposide
NED, 2 months
Park et al. 30 Vaginal bleeding, uterine
enlargement
IVB None Vincristine
Doxorubicin
Ifosfamide
Carboplatin
Etoposide
DOD, 16 months
Shah et al. (2009) 59 Vaginal bleeding, pelvic mass IIIC TAH, BSO, PLND, PALND,
omentectomy
Paclitaxel
Carboplatin
AWD, 12 months
Majeed et al. 27 Vaginal bleeding, uterine
mass
NR TAH/BSO Vincristine+
Etoposide+
Doxorubicin+
Ifosfamide/
Vincristine+
NED, 2 years
(continued on next page)
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Table 1 (continued)
Author Age Initial sign/symptom FIGO
stage
Surgery Chemotherapy Follow-up
Ifosfamide
Ren et al. 56 Vaginal bleeding IB TAH, BSO, PLND Ifosfamide
Etoposide
Cisplatin
NED, 41 months
Fukunaga et al. 54 Unknown NR TAH, BSO Cyclophosphamide
Cisplatin
Doxorubicin
5-FU
AWD, 3 months
Venizelos et al. 68 Vaginal bleeding I TAH, BSO Not done NED, 10 months
Euscher et al. (2008) 58 Vaginal bleeding with
palpable mass
IIIC Unknown surgery Not done DOD, 2 months
Euscher et al. (2008) 31 Back pain from metastatic
disease
IV Not done Unknown chemotherapy
regimen
DOD, 20 months
Euscher et al. (2008) 72 Vaginal bleeding IA Unknown Unknown DOD, 11 months
Euscher et al. (2008) 48 Unknown IIIC Unknown Unknown Unknown
Euscher et al. (2008) 81 Vaginal bleeding Unknown Unknown Unknown Unknown
Euscher et al. (2008) 66 Pelvic mass IIIC Unknown surgery Letrozole NED, 41 months
Euscher et al. (2008) 53 Vaginal bleeding Unknown Unknown Unknown DOD, 22 months
Euscher et al. (2008) 51 Vaginal bleeding Unknown Unknown Unknown DOD, 12 months
Euscher et al. (2008) 31 Vaginal bleeding Unknown Unknown Unknown DOD, 26 months
Euscher et al. (2008) 64 Cervical polyp IIB/
possible
IIIC
TAH, BSO Unknown chemotherapy
regimen
NED, 36 months
Euscher et al. (2008) 64 Vaginal bleeding with pain Unknown Unknown Unknown Unknown
Euscher et al. (2008) 69 Vaginal bleeding IV by
imaging
Unknown Unknown Unknown
Euscher et al. (2008) 62 Uterine ﬁbroids IIIC Unknown Unknown DOD, 22 months
Euscher et al. (2008) 55 Vaginal bleeding with
ﬁbroids
IB TAH, BSO Unknown chemotherapy
regimen
NED, 38 months
Euscher et al. (2008) 52 Unknown IV Unknown Unknown NED, 6 months
Euscher et al. (2008) 58 Vaginal pressure with
passage of tissue
IV Not done Unknown chemotherapy
regimen
NED, 6 months
Euscher et al. (2008) 57 Unknown IIIC Not done Unknown chemotherapy
regimen
NED, 35 months
Stolnicu et al. 12 Vaginal bleeding with
passage of tissue
Unknown Not done Etoposide, Bleomycin,
Cisplatin
NED, 36 months
Vignali et al. 31 Vaginal bleeding,
intermittent abdominal pain
IIIC Unknown Cisplatin, Etoposide NED, 24 months
Cate et al. 25 Vaginal bleeding, uterine
inversion and prolapse
Unknown TAH Not done NED, 18 months
Dizon et al. 50 Abdominopelvic pain Unknown TAH, BSO, omentectomy, Carboplatin, Etoposide NED, 16 months
Shimada et al. 63 Constipation Unknown TAH, BSO Cyclophosphamide,
Vincristine, Adriamycin
NED, 24 months
Yi et al. 29 Abdominal swelling and pain IVB TAH, BSO, PALND, PLND,
omentectomy
Neoadjuvant docetaxel and
carboplatin.
Vincristine, Adriamycin,
Cyclophosphamide
AWD, 18 months
Liver metastasis
Aminimoghaddam
et al.
32 Vaginal bleeding, abdominal
pain
TAH, BSO, PLND Holoxan, Mesna, Cisplatin,
Paclitaxol, Carboplatin
AWD, unknown
Current case 26 Vaginal bleeding, uterine
mass
IV TAH, BSO, omentectomy, PLND Carboplatin
Etoposide
Avastin
NED, 48 months
TAH, total abdominal hysterectomy; LSO, left salpingo-oophorectomy; DOD, died of disease; BSO, bilateral salpingo-oophorectomy; PALND; pelvic and para-aortic lymph node dissection;
RH, radical hysterectomy; PLND, pelvic lymph node dissection; NED, no evidence of disease; SCH, supracervical hysterectomy; AWD, alive with disease; NR, not recorded.
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tion of sheets and nests of cells with round to oval hyperchromatic nu-
clei, ﬁnely granular chromatin, conspicuousmultiple nucleoli, and scant
cytoplasm. Homer-Wright rosettes and pseudo-rosettes were frequent-
ly observed (Fig. 1a). Widespread lymphovascular invasion was pres-
ent, and mitotic ﬁgures were common (48/10 high power ﬁelds).
Immunohistochemical stains demonstrated that the tumor cells were
negative for CK 8/18, CK AE1/3, CD10, CD34, desmin, MSA, Myf-4,
GFAP, chromogranin, neuroﬁlament, CD99 and FLI1. Positive stains in-
cluded vimentin, CD56, NSE, and synaptophysin (Fig. 1b–c). Antibodies
against vascular endothelial growth factor (VEGF) (VG1 clone, Novus)
showed positive cytoplasmic staining (Fig. 1d). In addition, CD34 and
MSA highlighted a prominent network of endothelial cells within the
sheets and nests of small hyperchromatic cells (Fig. 1e–f). Fluorescence
in situ hybridization (FISH) analysis using a LSI EWSR1 dual color,break-apart probe (Abbot Molecular) revealed no evidence of EWSR1
gene rearrangement.2.2. Treatment
Following discussion of the patient's case at our institution's gyneco-
logic oncology tumor board, the decision was made to treat the patient
with six cycles of cisplatin and etoposide. Bevacizumab was added to
the regimen for the second through sixth cycles given the ﬁnding of as-
cites. Response to treatment was followed with physical examination,
serial CA-125 levels, and CT scans of the chest, abdomen and pelvis.
Baseline CA-125 was 372 U/mL. CA-125 levels obtained prior to
administration of the second through sixth cycles were 189 U/mL,
31 U/mL, 22 U/mL, 15 U/mL, and 15 U/mL respectively. Three months
29J. Novo et al. / Gynecologic Oncology Reports 14 (2015) 26–30following the last cycle, the CA-125 level was 12 U/mL. Her most recent
CA-125 was 10 U/mL, sixty-one months post-treatment.
A CT scan following the third cycle of cisplatin/etoposide/
bevacizumab showed resolution of ascites and pleural effusion with
mildly enlarged retroperitoneal lymph nodes. Three months after com-
pletion of chemotherapy, imaging showed stability of the retroperitone-
al lymph nodes without evidence of disease. Her most recent scan,
performed forty-eight months after completion of therapy, shows no
evidence of recurrence.
2.3. Toxicity
The patient tolerated the chemotherapywith resultant Eastern Coop-
erative Oncology Group (ECOG) Grade 3 nausea and vomiting which re-
quired hospitalization three times for IV hydration and IV antiemetics.
Because of ECOG Grade 3 neutropenia, she was given pegﬁlgrastim on
day 3 of each subsequent cycle. Given the patient's response to the che-
motherapy regimen of cisplatin/etoposide/bevacizumab in treating her
stage IV endometrial primitive neuroectodermal tumor, the patient wasFig. 1. The tumorwas composed of small hyperchromatic cellswith scant cytoplasm. Homer-Wr
(b), synaptophysin (c), and VEGF (d). A prominent vascular network was present (e), which isplaced on surveillance. At sixty-twomonths following treatment, the pa-
tient is disease-free based on tumor markers, physical examination, and
CT imaging studies.
3. Discussion
PNETs are small round cell tumors with glial, neural, and ependymal
differentiation, thought to be derived from fetal neuroectodermal tissue
(Hart & Earle, 1973). PNETs can be further classiﬁed based on degree of
differentiation, location and genetic signatures into peripheral and cen-
tral types. Peripheral-type PNET/Ewing sarcoma (pPNET/ES) is believed
to originate from neural crest and occur outside of the central nervous
system. Immunohistochemically, the great majority of pPNET/ES dem-
onstrate CD99 and FLI1 positivity, and cytogenetics demonstrate the
characteristic t(11;22)(q24;q12) translocation and EWSR1/FLI1 gene fu-
sion (Nogales, 2003; Varghese et al., 2006). cPNET/neuroblastoma are
derived from the central neuraxis and involve central structures includ-
ing the brain and spinal cord, and generally lack the EWSR1 gene rear-
rangement (Hart & Earle, 1973). The majority of primary uterineight rosettes and pseudo-rosetteswere present (a). The tumor cellswere positive for CD56
highlighted by CD34 (f).
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resemble a cPNET.
Uterine PNETs are rare tumors that typically present in postmeno-
pausal women although a minority present in the second decade,
highlighting a bimodal age distribution. Abnormal uterine bleeding is
the most common presenting symptom, and a uterine mass the most
common ﬁnding on exam. Uterine PNETs are frequently diagnosed at
an advanced stage, highlighting their aggressive nature. The two-year
survival of younger patients and postmenopausal patients has been re-
ported as 75% and 32%, respectively (Odunsi et al., 2004). Factors that
portend a poor prognosis for the PNET family of tumors include meta-
static disease at presentation (as conﬁrmed by imaging, as well as cyto-
logic and histologic examination of the bone marrow), primary
extraosseous tumor, central or pelvic disease, age at diagnosis of 26 or
older, tumor size greater than 8 cm, poor response to chemotherapy, ab-
sence of EWS-FLI1 fusion gene, and elevated pretreatment LDH (Mittal
et al., 2007; Burchill, 2003).
There is no consensus regarding the optimal treatment of uterine
PNETs. Patients treated with surgery and radiation have a relapse rate
approaching 90% (Blattner et al., 2007). Multimodal therapy improves
disease free survival, but the optimal chemotherapeutic regimen has
not yet been demonstrated (Shah et al., 2009). Our patient underwent
surgical managementwith optimal debulking as deﬁned bymeasurable
disease less than 1 cm followed by adjuvant chemotherapy alone. We
chose to treat this patient with cisplatin and etoposide. Because the pa-
tient exhibited a large amount of ascites intraoperatively, as well as
pleural effusion on post-operative imaging, the decision was made to
add bevacizumab, a humanized monoclonal antibody directed against
VEGF, to this regimen. VEGF has been implicated as a stimulator of vas-
cular permeability, a contributing factor to malignant ascites (Mesiano
et al., 1998). Because she did not exhibit any evidence of disease follow-
ing chemotherapy, she did not receive post-operative radiation.
Due to the rare nature of uterine PNET and few case reports in the lit-
erature, it is difﬁcult to determine the optimal course of treatment. Be-
cause cases of PNET are so rare, it is also problematic to accurately
predict rates of survival or recurrence of this particular type of malig-
nant neoplasm. To date there have been no case reports in the literature
using the combination of cisplatin/etoposide/bevacizumab for adjuvant
treatment of uterine PNET. Bevacizumab has been previously shown to
be a potential therapeutic modality in vitro (Dalal et al., 2005), and a
case series exploring its therapeutic value in the management of recur-
rent medulloblastoma have yielded objective response rates (Aguilera
et al., 2013). Oberstein et al. reviewed three phase II clinical trials
employing bevacizumab in the management of pancreatic neuroendo-
crine carcinomas, including PNET, showing a partial response rate rang-
ing from 0 to 56% and mean progression-free survival ranging from 4.2
months to 23.7 months (Oberstein & Saif, 2012).
The presence of neoplastic endothelial proliferation and VEGF posi-
tivity within the tumor provides a rational explanation to theeffectiveness of this novel chemotherapy modality against uterine
cPNET. This treatment option was tolerated by our patient with the
side effects of Grade 3 nausea, which was supported with hospitaliza-
tion and administration of IV ﬂuids and antiemetics, and Grade 3 neu-
tropenia, which was improved by the addition of pegﬁlgrastim and
supportive care. Based on our patient's histopathologic and immunohis-
tochemical features of this particular cPNET, and the favorable response
to treatment using cisplatin/etoposide/bevacizumab, prospective clini-
cal trials are required to evaluate the efﬁcacy of this treatment schema
in the management of advanced-stage uterine cPNET.
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